nach oben

Erschienen in:

28.02.2018 | Review Article

Mast cells and angiogenesis in pancreatic ductal adenocarcinoma

verfasst von: Vito Longo, Roberto Tamma, Oronzo Brunetti, Salvatore Pisconti, Antonella Argentiero, Nicola Silvestris, Domenico Ribatti

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Mast cells are recognized as critical components of the tumor stromal microenvironment in several solid and hematological malignancies, promoting angiogenesis and tumor growth. A correlation between mast cells infiltration, angiogenesis and tumor progression has been reported for pancreatic ductal adenocarcinoma as well. Mast cells contribute to the aggressiveness of the pancreatic ductal carcinoma enhancing the expression of several pro-angiogenic factors such as vascular endothelial growth factor, fibroblast growth factor-2, platelet-derived growth factor and angiopoietin-1 as well as stimulating the pancreatic cancer cells proliferation by IL-13 and tryptase. The disruption of this pro-angiogenic and proliferative stimulation by inhibiting the mast cells migration and degranulation is under investigation as a potential therapeutic approach in pancreatic ductal adenocarcinoma patients. This review will summarize the literature concerning the mast cells infiltration in the pancreatic ductal adenocarcinoma analyzing its role in angiogenesis and tumor progression.

Ribatti D. The development of human mast cells. An historical reappraisal. Exp Cell Res. 2016;342(2):210–5. https://doi.org/10.1016/j.yexcr.2016.03.013.CrossRefPubMed

da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62(10):698–738. https://doi.org/10.1369/0022155414545334.CrossRefPubMedPubMedCentral

Vukman KV, Försönits A, Oszvald Á, Tóth EÁ, Buzás EI. Mast cell secretome: soluble and vesicular components. Semin Cell Dev Biol. 2017;67:65–73. https://doi.org/10.1016/j.semcdb.2017.02.002.CrossRefPubMed

Lässer C, Shelke GV, Yeri A, et al. Two distinct extracellular RNA signatures released by a single cell type identified by microarray and next-generation sequencing. RNA Biol. 2017;14(1):58–72. https://doi.org/10.1080/15476286.2016.1249092.CrossRefPubMed

Ribatti D, Crivellato E. Mast cells, angiogenesis and cancer. Adv Exp Med Biol. 2011;716:270–88. https://doi.org/10.1007/978-1-4419-9533-9_14.CrossRefPubMed

Kinet J-P. The essential role of mast cells in orchestrating inflammation. Immunol Rev. 2007;217:5–7.CrossRefPubMed

Pittoni P, Piconese S, Tripodo C, Colombo MP. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene. 2011;30:757–69.CrossRefPubMed

Ribatti D, Crivellato E. Mast cell ontogeny: an historical overview. Immunol Lett. 2014;159:11–4.CrossRefPubMed

Huang B, Lei Z, Zhang G-M, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008;112:1269–79.CrossRefPubMedPubMedCentral

10.

Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–29. https://doi.org/10.1016/j.ccr.2012.01.007.CrossRefPubMedPubMedCentral

11.

Büchler P, Reber HA, Büchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003;26(1):56–64.CrossRefPubMed

12.

Shibaji T, Nagao M, Ikeda N, et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 2003;23(6C):4721–7.PubMed

13.

Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–20. https://doi.org/10.1136/gutjnl-2012-302529.CrossRefPubMed

14.

Longo V, Brunetti O, Gnoni A, et al. Angiogenesis in pancreatic ductal adenocarcinoma: a controversial issue. Oncotarget. 2016;7(36):58649–58. https://doi.org/10.18632/oncotarget.10765.CrossRefPubMedPubMedCentral

15.

Gnoni A, Licchetta A, Scarpa A, et al. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci. 2013;14(10):19731–62. https://doi.org/10.3390/ijms141019731.CrossRefPubMedPubMedCentral

16.

Karamitopoulou E, Shoni M, Theoharides TC. Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis. Int J Immunopathol Pharmacol. 2014;27(2):213–20.CrossRefPubMed

17.

Esposito I, Menicagli M, Funel N, et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol. 2004;57(6):630–6.CrossRefPubMedPubMedCentral

18.

Strouch MJ, Cheon EC, Salabat MR, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res. 2010;16(8):2257–65. https://doi.org/10.1158/1078-0432.CCR-09-1230.CrossRefPubMedPubMedCentral

19.

Chang DZ, Ma Y, Ji B, et al. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011;17(22):7015–23. https://doi.org/10.1158/1078-0432.CCR-11-0607.CrossRefPubMedPubMedCentral

20.

Cai SW, Yang SZ, Gao J, et al. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery. 2011;149(4):576–84. https://doi.org/10.1016/j.surg.2010.10.009.CrossRefPubMed

21.

Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res. 2013;73(13):3927–37. https://doi.org/10.1158/0008-5472.CAN-12-4479.CrossRefPubMedPubMedCentral

22.

Zhan HX, Zhou B, Cheng YG, et al. Crosstalk between stromal cells and cancer cells in pancreatic cancer: new insights into stromalbiology. Cancer Lett. 2017;28(392):83–93. https://doi.org/10.1016/j.canlet.2017.01.041.CrossRef

23.

Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. Eur J Cancer. 2014;50(15):2570–82. https://doi.org/10.1016/j.ejca.2014.06.021.CrossRefPubMed

24.

Cimpean AM, Tamma R, Ruggieri S, Nico B, Toma A, Ribatti D. Mast cells in breast cancer angiogenesis. Crit Rev Oncol Hematol. 2017;115:23–6. https://doi.org/10.1016/j.critrevonc.2017.04.009.CrossRefPubMed

25.

Zudaire E, Martínez A, Garayoa M, et al. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol. 2006;168(1):280–91.CrossRefPubMedPubMedCentral

26.

Varricchi G, Galdiero MR, Loffredo S, Marone G, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8(424):2017. https://doi.org/10.3389/fimmu.2017.00424.CrossRef

27.

Guo X, Zhai L, Xue R, Shi J, Zeng Q, Gao C. Mast cell tryptase contributes to pancreatic cancer growth through promoting angiogenesis via activation of angiopoietin-1. Int J Mol Sci. 2016;17(6):E834. https://doi.org/10.3390/ijms17060834.CrossRefPubMed

28.

Ammendola M, Sacco R, Sammarco G, et al. Mast cells density positive to tryptase correlates with angiogenesis in pancreatic ductal adenocarcinoma patients having undergone surgery. Gastroenterol Res Pract. 2014. https://doi.org/10.1155/2014/951957.PubMedPubMedCentralCrossRef

29.

Silvestris N, Gnoni A, Brunetti AE, et al. Target therapies in pancreatic carcinoma. Curr Med Chem. 2014;21(8):948–65. https://doi.org/10.2174/09298673113209990238.CrossRefPubMed

30.

Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23(31):8033–40. https://doi.org/10.1200/JCO.2005.01.9661.CrossRefPubMed

31.

https://clinicaltrials.gov/ct2/show/NCT02179970?term=amd3100++pancreatic&rank1.

32.

Theoharides TC. Mast cells and pancreatic cancer. N Engl J Med. 2008;358(17):1860–1. https://doi.org/10.1056/NEJMcibr0801519.CrossRefPubMed

33.

Ammendola M, Leporini C, Marech I, et al. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014;2014:154702. https://doi.org/10.1155/2014/154702.CrossRefPubMedPubMedCentral

34.

Francis T, Graf A, Hodges K, et al. Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. Hepatobiliary Surg Nutr. 2013;2(4):216–26. https://doi.org/10.3978/j.issn.2304-3881.2013.08.06.PubMedPubMedCentralCrossRef

35.

Wang ZY, Ding Y, Miki T, et al. Nerve growth factor and receptors are significantly affected by histamine stimulus through H1 receptor in pancreatic carcinoma cells. Mol Med Rep. 2010;3(1):103–9. https://doi.org/10.3892/mmr_00000225.PubMedCrossRef

36.

Cricco G, Núñez M, Medina V, et al. Histamine modulates cellular events involved in tumour invasiveness in pancreatic carcinoma cells. Inflamm Res. 2006;55(Suppl 1):S83–4.CrossRefPubMed

37.

Humbert M, Castéran N, Letard S, et al. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE. 2010;5(3):e9430. https://doi.org/10.1371/journal.pone.0009430.CrossRefPubMedPubMedCentral

38.

Deplanque G, Demarchi M, Hebbar M, et al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015;26(6):1194–200. https://doi.org/10.1093/annonc/mdv133.CrossRefPubMedPubMedCentral

Titel: Mast cells and angiogenesis in pancreatic ductal adenocarcinoma
verfasst von: Vito Longo
Roberto Tamma
Oronzo Brunetti
Salvatore Pisconti
Antonella Argentiero
Nicola Silvestris
Domenico Ribatti
Publikationsdatum: 28.02.2018
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 3/2018
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-018-0493-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

The role of the alternative pathway of complement activation in glomerular diseases

Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment

The complex alteration in the network of IL-17-type cytokines in patients with hereditary angioedema

Reduced mitochondrial DNA content in lymphocytes is associated with insulin resistance and inflammation in patients with impaired fasting glucose

Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation